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Abstract: Crohn’s disease (CD) is a chronic inflammatory condition involving the gastrointestinal 
tract characterized by recurrent exacerbations and remission. The disease frequently occurs in the 
lower part of the small bowel, but can affect any part of the digestive tract, from the mouth to the 
anus. The traditional goals of treatment of Crohn’s disease were to induce and maintain clinical 
remission. More recently targets such as mucosal healing, reduced hospitalization and surgery, 
and improved quality of life are becoming increasingly achievable. The general principles for 
treatment should consider clinical activity, site and behavior of disease; however, the appropriate 
choice of medication depends on many factors that are the best tailored to the individual patient. 
This review focuses on certolizumab pegol, the first Fc-free PEGylated Fab' fragment of human-
ized monoclonal antibody that binds and neutralizes human tumor necrosis factor alpha. Data on 
indication, pharmacokinetics, efficacy, safety, and influence on quality of life are reviewed.
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Introduction
Crohn’s disease is a chronic inflammatory condition involving the gastrointestinal tract 
characterized by recurrent exacerbations and remission. The disease frequently occurs 
in the lower part of the small bowel, but can affect any part of the digestive tract, from 
the mouth to the anus. The most common symptoms are abdominal pain, often in the 
lower right region of the abdomen, diarrhea, often with blood and/or mucus in the 
stool, weight loss, anorexia, fever, and extra-intestinal manifestations (ie, localized to 
the eyes, skin, and joints).1. In addition, approximately 10% of Crohn’s disease patients 
have perianal fistulas at the diagnosis.2
The goal of treatment should be to induce clinical remission, while bearing in 
mind the most appropriate means of maintaining remission. This actually may require 
a “step up” regimen, where less potent/toxic approaches are used as first-line therapy, 
although in selected patients, a “top down” approach using as first-line biological 
therapy could be appropriate.
Epidemiology, genetic background  
and pathogenesis
A consistent geographical variation in incidence rates has been reported varying from 
3.6 to 15.6 cases per 100,000 person-years in North America, 0.7 to 9.8 cases per 
100,000 in Europe, and 0.5 to 4.2 cases per 100,000 in Asia.3
The wide regional and racial variation suggests an important genetic component 
in the pathophysiology of the disease or a distinct environmental contribution.Clinical and Experimental Gastroenterology 2009:2 62
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The disease tends to occur slightly more frequently in 
women (50% to 60%) than in men,4 and while most patients 
are diagnosed in their twenties and thirties, about 10% to 
15% are diagnosed in childhood.5
Crohn’s disease is widely believed to originate from 
a dysregulated immune response to luminal bacteria, in 
a genetically susceptible host.6 The inheritance model is 
non-Mendelian but complex–polygenic, with several genes 
involved together and interacting with environmental 
factors.
Concordance data in monozygotic twins (36% to 58%) 
and the high relative risk for first-degree relative (up to 20 to 
35) have provided strong epidemiological evidence for a 
genetic contribution.7 These observations led to development 
of genetic investigations with two broad strategies: one 
has investigated candidate genes whereas the other used 
hypothesis-free methods like genome-wide scanning.
The NOD2 gene (nucleotide-binding oligomerization 
domain 2) on chromosome 16q12 was the first susceptibility 
gene for Crohn’s disease to be successfully identified in 2001 
among Caucasians.8 NOD2 gene encodes an intracellular 
receptor predominantly expressed in monocytes and Paneth 
cells.9 The coded protein is activated by muramyldipeptide 
(MDP), a component of peptidoglycan in bacterial cell walls 
and subsequently will activate the nuclear factor-κB signaling 
pathway, and stimulate secretion of antimicrobial peptides 
including defensins.10 NOD2 variants are more prevalent in 
patients with ileal Crohn’s disease and seems to predispose 
for a stricturing phenotype and need for surgery.11–16
More recently, a number of genome-wide association 
studies17 and a meta-analysis18 have identified more than 
30 Crohn’s disease susceptibility loci.
The contribution of environmental factors is more 
puzzling. Given that the incidence of disease appears to 
increase as countries become more developed, it is likely that 
some components of disease are triggered by an industrial 
environmental (diet or changes in exposure to pathogens); 
moreover, higher incidence of disease is associated with 
higher socioeconomic status.9 Of the environmental factors 
thought to affect disease susceptibility, only smoking and 
appendectomy have a substantive evidence base.3,20
In conclusion, the current hypothesis on pathogenesis 
suggests that Crohn’s disease is the result of an exaggerated 
immune response against intestinal microflora by activation 
of T cells and overexpression of inflammatory cytokines in 
a genetically predisposed host.18 The classic immunological 
paradigm focuses especially on type 1 helper T-cell (Th1) 
cytokines, especially tumor necrosis factor alpha (TNF-α), 
although more recently the Th17 pathway is receiving increasing 
attention.21,22
Principles of medical therapy
The main goal of the treatment of Crohn’s disease is to induce 
clinical remission. The appropriate choice of medication 
depends on many factors that are the best tailored to indi-
vidual patient. The choice is often influenced by the balance 
between drug potency and site effects, previous response to 
treatment, or presence of extra-intestinal manifestation.
New therapeutic approaches over the last decade have 
focused on the immunological mechanisms associated with 
the pathogenesis of Crohn’s disease, especially the blocking 
of TNF-α.
TNF is a proinflammatory cytokine which is a key media-
tor of inflammation. It can be detected at high concentrations 
in diseased areas of the bowel wall and in blood and feces of 
patients.26–28 AntiTNF-α acts by binding to both soluble and 
trans-membrane forms of TNF-α, inhibiting its immediate 
pro-inflammatory actions, and the production of other pro-
inflammatory mediators. In vitro studies have demonstrated 
that antiTNF-α agents reduce the production of chemo-
kines and upregulation of endothelial adhesion molecules; 
this in turn decreases the migration of inflammatory cells, 
reduces granulocyte-macrophage colony-stimulating factor 
(GM-CSF) production in intestinal mucosal T cells, and may 
in turn induce T cells apoptosis.
Infliximab was the first antiTNF-α antibody approved by 
FDA for treatment of Crohn’s disease. However, its chimeric 
composition has been associated with problems of immuno-
genicity, which may lead to infusion reactions and loss of 
efficacy.29 More recently several other biologics have been 
investigated for treatment of Crohn’s disease: adalimunab, 
natalizumab, CDP871, and certolizumab. The last named has 
been approved by FDA for adults with moderate to severe 
Crohn’s disease not responding to conventional therapy.30
Our aim is to provide a comprehensive, up-to-date review 
of indication, pharmacokinetics, efficacy, safety, and influ-
ence on quality of life of certolizumab.
Mechanism of action  
of certolizumab pegol (CDP870)
Certolizumab pegol is the first Fc-free PEGylated Fab ´ 
fragment of humanized monoclonal antibody that binds and 
neutralizes human TNF-α. The pharmacokinetic properties 
of the Fab' fragment in vivo are usually poor. However, 
attachment of the 40 kDa polyethylene glycol (PEG) moiety 
markedly increases the half-life of certolizumab to a value Clinical and Experimental Gastroenterology 2009:2 63
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comparable with that of the whole-antibody product. The 
Fab ´ fragment was engineered with a single free-cysteine 
residue in the hinge region, which enables site-specific 
attachment of PEG without affecting the ability of the Fab ´ 
fragment to bind and neutralize TNF-α. The structure of 
certolizumab pegol differs from that of other antiTNF-α 
agents that have been tested for treatment of Crohn’s disease. 
Infliximab, adalimumab, and etanercept are all based on 
the human IgG1 Fc, are capable of fixing complement and 
binding to Fc receptors, and therefore have the potential for 
Fc-mediated effect.
The mechanisms of action believed to be essential for the 
efficacy of antiTNF-α agents in Crohn’s disease are:
Induction of apoptosis of both monocytes and T cells;31–34
Neutralization of soluble and membrane-bound TNF-α;33
Antibody-dependent cell-mediated cytotoxity (ADCC) 
and complement-dependent cytotoxity (CDC);35
Reverse signaling via mTNF-α.36
In vitro studies have demonstrated that infliximab, 
certolizumab, adalimumab, and etanercept are all able to 
neutralize soluble TNF-α and membrane-bound TNF-α. 
Infliximab and adalimumab are comparable in their ability 
to mediate complement-dependent cytotoxicity, and 
antibody-dependent cell-mediated cytotoxicity. Moreover, 
they equally increase the proportion of cells undergoing 
apoptosis and the level of granulocyte degranulation. 
Etanercep mediated these effects to a lesser degree, while 
certolizumab pegol did not exhibit increased levels of 
apoptosis, suggesting that these mechanisms are not essential 
for the efficacy of antiTNF-α agents in Crohn’s disease.32 
This probably happens because certolizumab pegol does not 
contain Fc region, which is normally present in a complete 
antibody, and therefore does not fix complement or cause 
antibody-dependent cell-mediated cytotoxicity.38
Despite the fact that certolizumab pegol is a monovalent 
antibody fragment, its in vitro potency is greater than that of 
bivalent antibody adalinumab and infliximab.39
The site-specific addition of two molecules of PEG to the 
antibody fragment increases the plasma half-life to approxi-
mately 2 weeks, thus reducing the frequency of dosing.
Efficacy study of certolizumab 
pegol (CDP870)
At the moment three clinical trials have evaluated the short-term 
efficacy of certolizumab for induction of clinical response and 
remission in patients with active Crohn’s disease.40
In these studies the clinical response was defined as a 
decrease of 100 points from baseline Crohn’s Disease 
Activity Index (CDAI) and remission was defined as a CDAI 
score of 150 points.
The phase II trial by Winter41 was a randomized, multi-
center, placebo-controlled study, which aimed to evaluate the 
efficacy and safety of a single intravenous (iv) administra-
tion of different doses of certolizumab in adult patients with 
moderate to severe Crohn’s disease. At the screening, patients 
were randomized into four treatment groups: certolizumab 
1.25 mg/kg, 5 mg/kg, 20 mg/kg, or placebo. The 5 mg/kg dose 
of certolizumab was equivalent to a 400 mg subcutaneous 
dose of certolizumab. Ninety-two adult patients were enrolled 
into the study and were permitted to receive concomitant 
medication (azathioprine, methotrexate, antibiotics, mesala-
zine, corticosteroids) provided that dose had been stable prior 
to the start of the study. No significant differences in baseline 
demographics between treatment groups were found.
At week 4 (primary endpoint) there were no statisti-
cally significant differences in clinical response for any of 
the certolizumab groups compared with placebo (Table 1). 
A post-hoc analysis at week 2 indicated that the certolizumab 
10 mg/kg dose had induced remission in a statistically signifi-
cant number of patients compared with placebo: 47.0% (95% 
CI 0.4–73.7) vs 16% (95% CI 0.0–32.4) (p = 0.041). More-
over, at week 4 47.1% of patients treated with certolizumab 
10 mg/kg were in remission compared with 20% of placebo 
group. However, these rates of response were not sustained 
at week 12 when only 23.5% of patients in certolizumab 
10 mg/kg were in remission compared with 32% of patients 
in the placebo group.
The lack of difference of clinical response between the 
certolizumab-treated groups and placebo was probably due 
to the high response rate observed in the placebo group 
(52% to 60%). This finding was in contrast to the relatively 
low placebo response rate observed in a similar study with 
infliximab (12% to 17%). Patient response rate may be influ-
enced by a variety of factors, such as use of corticosteroids, 
surgery and concomitant therapy. In addition, high placebo 
response rates may also be an artifact of the calculation of 
CDAI score, because of the high degree of subjectivity of 
this index as an indicator of disease activity.
Table 1 Clinical response to certolizumab pegol (CDP870) vs 
placeb at week 441
CDAI CDP870 dose Placebo
5 mg/kg 10 mg/kg 20 mg/kg
response (%) 60.0 58.8 47.8 56.0%
(95% Ci) (38.8–81.2) (32.5–85.2) (25.2–70.4) (34.5–77.5)Clinical and Experimental Gastroenterology 2009:2 64
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The phase II, multicenter, randomized, double-blind 
placebo-controlled, dose-response trial by Schreiber et al was 
designed to assess the efficacy and safety of subcutaneous 
certolizumab 100 mg, 200 mg, 400 mg, or placebo adminis-
tered at week 0, 4, and 8.42 Efficacy assessments were performed 
every 2 week up to week 12, with a further 8-week follow-up 
evaluation for safety. A total of 291 patients were included 
in the study. Concomitant therapy with steroids, mesalamine 
or immunosuppressants was permitted if the patient was on 
a stable dose that could be continued throughout the 12-week 
duration of the double-blind phase. Patient characteristics were 
generally well balanced among treatment groups, although 
the mean age of patients receiving certolizumab was higher 
than in the placebo group. The greatest difference among the 
groups was a small preponderance of women in the placebo 
group. The use of concomitant medications were broadly 
similar among groups; the greater difference was observed 
for overall glucocorticoid use: 39.7% in the placebo group 
and 30.6% in the certolizumab 400 mg group.
For the primary endpoint, all doses of certolizumab pro-
duced at week 2 a statistical benefit compared with placebo 
(Table 2). Certolizumab also showed significantly higher 
efficacy compared with placebo at week 4, 8, and 10 (only 
for 400 mg dose). Patients receiving the 400 mg dose showed 
the highest response rate at all time points, with the highest 
response observed at week 10 (52.8% vs 30.1% in placebo 
group). However, at week 12 the difference between the cer-
tolizumab- and placebo-treated groups did not reach statistical 
significance. There was no effect of gender or concomitant 
therapy on the clinical response rate. The same was observed 
for the remission rate at weeks 4 and 12. A post-hoc analysis 
according to baseline C-reactive protein (CRP) concentra-
tion was performed since CRP serum concentration usually 
provides an objective criterion of inflammatory activity.43 
Increased serum concentrations of CRP have been reported 
as a regular feature of patients with active disease. In asymp-
tomatic patients, increased levels of this protein may indicate 
subsequent clinical relapse. Indeed, in patients with baseline 
CRP levels of 10 mg/L or greater, treatment with certolizumab 
400 mg resulted in a statistically significant benefit at all time 
points throughout the 12-week study in terms of both rates 
of clinical response and remission. In patients with baseline 
CRP less than 10 mg/L, none of active treatments achieved a 
statistical difference from placebo, both of clinical response 
and remission rates. In patients with baseline CRP concentra-
tion 7 to 10 mg/L who received certolizumab 400 mg, the 
clinical response rates at week 12 showed statistically signifi-
cant difference from placebo. Accordingly, placebo response 
rates decreased with increasing baseline CRP level.
The phase III randomized, double-blind, placebo-controlled 
trial by Sandborn et al PRECISE 1 (Pegylated anti-
body fRagment Evaluation in Crohn’s dIsease: safety 
and Efficacy 1)44 was designed to evaluate the efficacy 
and safety of certolizumab 400 mg or placebo subcutane-
ously at week 0, 2, 4 and then every 4 weeks. Patients were 
followed through week 26. Randomization was performed 
centrally and was stratified according to the serum level 
of CRP (10 mg/L 10 mg/L) and concomitant therapy. 
Patients could receive concomitant therapy with stable 
doses of mesalamine, steroids, and immunosuppressive 
drugs. The baseline characteristics were similar in the two 
groups of patients. The study was conduct on 662 adults with 
moderate-to severe Crohn’s disease. Among patients with a 
baseline CRP level of at least 10 mg/L, 37% of patients in the 
certolizumab groups had a response at week 6 as compared 
with 26% in placebo group (p = 0.04). In the overall popula-
tion, response rates at week 6 were 35% in the certolizumab 
group and 27% in the placebo group (p = 0.02). At weeks 
6 and 26, 23% of patients in the certolizumab groups had a 
response compared with 16% of patients in the placebo group 
(p = 0.02). Use of immunosuppressive agents, concomitant 
steroids, previous treatment with infliximab and smoking 
status were not associated with the magnitude of response. 
At week 26, 30% of patients in the certolizumab group had 
fistula closure as compared with 31% in the placebo group.
Another important endpoint is to achieve and main-
tain long-term remission in Crohn’s disease. Two studies 
have assessed the long-term efficacy of certolizumab for 
maintenance of response and remission, PRECISE 245 and 
PRECISE 3.46 In PRECISE 2, there was an induction phase 
in which 668 patients received three subcutaneous injections 
doses of certolizumab 400 mg at week 0, 2, and 4. At week 6, 
64.1% patients (428/668) had clinical response and were 
than randomized to the maintenance phase, receiving certoli-
zumab 400 mg/kg or placebo every 4 weeks up to week 26. 
At week 26, in the certolizumab group response rate was 
63% compared with 36% in the placebo group (p  0.001); 
in addition, 48% of patients in the certolizumab group had 
Table 2 Global benefit at week 2 post-injection of certolizumab 
pegol (CDP870) vs placebo42
Placebo 15.1% (95% CI, 6.2–24.0)
CDP870 100 mg 29.7% (95% Ci, 18.6–40.8) (p = 0.033)
CDP870 200 mg 30.6% (95% Ci, 19.2–41.9) (p = 0.026)
CDP870 400 mg 33.3% (95% Ci, 21.8–44.9) (p = 0.010)Clinical and Experimental Gastroenterology 2009:2 65
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remission at week 26 compared with 29% in the placebo 
group (p  0.001).
The study was centrally randomized and group 
assignment was stratified according to serum CRP level 
(10 mg/L or 10 mg/L), concurrent use of steroids, and 
immunosuppressive agents. In the intention to treat analysis, 
response rates at week 26 were greater among patients 
receiving maintenance therapy with certolizumab than among 
those receiving placebo, both for patients receiving concomi-
tant immunosuppressive agents (61% vs 33%) (p  0.001) 
and those without (64% vs 39%) (p  0.001). No significant 
interactions between group assignment and smoking status 
or body mass index were found.
Among patients with a baseline CRP serum level of less 
than 10 mg/L, response rates at week 26 were significantly 
greater in the certolizumab group (64%) compared with 
placebo groups (39%) (p  0.001); similarly remission rate 
was 54% in the certolizumab group compared with 31% in 
the placebo group (p  0.001).
The PRECISE 3 was an open label extension study that 
recruited patients from PRECISE 1 and 2. Patients enrolled 
received certolizumab 400 mg subcutaneously every 4 weeks. 
Two populations were analyzed: patients induced and treated 
for 24 weeks with certolizumab (PRECISE 1 and 2); patients 
who responded to induction therapy with certolizumab, but 
were than randomized to placebo in PRECISE 2.
At week 80, more than 80% of patients achieved a 
clinically meaningful response and remission rate. Therefore, 
certolizumab 400 mg administered every 4 weeks was an 
effective long-term maintenance therapy for patients who 
had responded to certolizumab induction therapy.
PRECISE 4 was an open label extension study that 
assessed the effectiveness of re-induction followed by 
maintenance therapy with certolizumab in patients who 
had experienced a significant clinical worsening of Crohn’s 
disease.47 Patients who withdrew after week 2 in PRECISE 
1 or week 6 in PRECISE 2 with clinical worsening entered 
in PRECISE 4 and received re-induction with certolizumab 
400 mg subcutaneously at week 0, 2, 4 and then every 
4 weeks. The rates of response at week 4 (45.7%), 24 (57.1%) 
and 52 (69.3%) indicated that re-induction with a single dose 
of certolizumab followed by a standard 4-weekly stable dose 
could restore clinical response and remission.
Another important issue to evaluate is the efficacy of 
certolizumab in patients previously treated with infliximab.
About one third of patients with active Crohn’s disease 
who had been treated with infliximab had no response to this 
drug after three induction doses.48 In addition, about one third 
of patients who might initially respond to infliximab therapy 
may subsequently lose the response or become intolerant over 
the first year of therapy. In PRECISE 2 a significant differ-
ence in the response rate at week 26 between the certolizumab 
group and the placebo group was found for patients who had 
previously received infliximab (44% vs 25%) (p  0.001).
In WELCOME, a 26-week open label induction, 
double-blind maintenance trial,40,49 539 patients who had 
loss of response or intolerance to infliximab received cer-
tolizumab 400 mg subcutaneously at weeks 0, 2, and 4. 
At week 6, 62.2% patients had clinical response and 39.3% 
had remission.
These data were confirmed a study that reported the 
efficacy of certolizumab for induction of response and 
remission in a case series of 21 Crohn’s disease patients 
who were refractory or had lost response to infliximab.50 
At week 4, 52% patients achieved clinical response and 
42% were in remission.40,50 These findings are in contrast 
with CHARM,51 which reported efficacy of adalimumab as 
maintenance therapy for moderate to severe Crohn’s disease. 
In this trial, patients who were naïve to antiTNF therapy had 
slightly better results at weeks 26 and 56 than patients who 
had previously received antiTNF therapy; however the dif-
ference did not reach statistical significance.
The concomitant use of immunomodulator with an 
antiTNF agent has been a topic of great interest and debate. 
Initially, it was assumed that the use of concomitant immu-
nomodulators could improve the efficacy of antiTNF-α 
therapy (specifically infliximab), probably by decreasing 
immunogenicity. Subsequently, data emerged suggesting 
that the efficacy of TNF antagonists used as monotherapy 
was equivalent to combination therapy with TNF antago-
nists and immunomodulators.52 Preliminary data from the 
pivotal SONIC (Study of Biologic and Immunomodula-
tor Naive Patients in Crohn’s Disease) trial have been 
reported.53 This study compared the efficacy outcomes in 
patients with Crohn’s disease naïve to immunomodulators 
treated with azathioprine, infliximab, or a combination of 
azathioprine and infliximab. Patients eligible for the study 
had received previous treatment only with corticosteroids 
and/or 5-aminosalicylates. Due to the characteristics of 
the inclusion criteria, patients had a short duration of 
Crohn’s disease, approximately 2 years before study entry. 
Week 26 steroid-free remission (CDAI  150) was the 
primary endpoint, with week 54 endoscopic remission as a 
second important endpoint. At week 26, patients receiving 
azathioprine in combination with infliximab had the highest 
rate of remission (57%) compared with infliximab alone Clinical and Experimental Gastroenterology 2009:2 66
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(44%) or azathioprine alone (30%). Endoscopic remission 
rates paralleled clinical remission rates, and patients on 
combination therapy fared the best, while those receiving 
infliximab alone fared second best, and those on azathioprine 
alone fared the worst. Mucosal healing at week 26 was 
shown in 43.9% of the patients treated with infliximab + 
azathioprine, 30.1% of those treated with infliximab alone, 
and 16.5% of those treated with azathioprine alone.
Certolizumab safety
A recently study51 analyzed the safety data collected 
from patients who were enrolled in the different clinical 
trials using certolizumab. 1313 patients who had received 
continuous treatment with certolizumab 400 mg were 
entered in the study. All patients received  4 week of 
certolizumab and were stratified into 4 groups based 
on the duration of treatment ( 3 months;  6 months; 
 9 months;  12 months). Rates of common adverse event 
were stable across exposure categories with the exception 
of infections, which increased with duration of exposure to 
certolizumab (47.5% if  4 weeks vs 60% if  6 months).
In PRECISE 1 there were 4 cases of cancer (2 in the 
certolizumab group and 2 in the placebo group) and 7 cases 
of serious infections (2%) in the certolizumab group and 
3 cases in the placebo group (1%).
In PRECISE 2 serious adverse events occurred in 6% of 
patients in the certolizumab group and 7% in the placebo 
group.
Although these results indicate that certolizumab does 
not increase the risk of serious adverse events, they should be 
interpreted with caution because the sample size was not large 
and the follow up might not have been long enough to pick up 
serious adverse events. Moreover, differences in the molecular 
structure compared with the other antiTNF agents may explain 
the different side-effects but data are lacking thus far.
Another issue is the potential development of anti-
certolizumab antibodies and their clinical implications. In 
Schreiber’s study,45 anticertolizumab antibodies were found 
in the 12.3% of patients receiving certolizumab 400 mg while 
in PRECISE I anticertolizumab antibodies were found in 
the 8% of patients and 4% of those receiving concomitant 
immunosuppressive therapy.44 The plasma concentration of 
certolizumab appeared to be lower in the presence of antibod-
ies, but no decrease in efficacy was reported.
Comparative efficacy of infliximab, 
adalimumab and certolizumab
Three antiTNF agents have been approved by the FDA for 
treatment of Crohn’s disease (Table 3). However it is dif-
ficult to directly compare the efficacy of certolizumab with 
infliximab and adalimumab in the absence of head-to-head 
studies. Nevertheless, the results of maintenance trials of 
these three drugs are similar; basically patients who had a 
clinical response at an early time point were randomized to 
receive either placebo or antiTNF agents and the rates of 
remission were taken at weeks 26 and 30.
In ACCENT1,52 the maintenance trial with infliximab, 
58% of patients responded to open label therapy at week 2 and 
30; 39% of patients were in remission on infliximab 5 mg/kg 
compared with 21% patients receiving placebo.
In CHARM,53 the maintenance trial with adalimumab, 
58% patients responded to open label therapy at week 4 and 
26 compared with 40% patients receiving placebo.
In PRECISE 2 study,45 64% patients responded to 
certolizumab 400 mg; 48% were in remission compared 29% 
patients in the placebo group.
Therefore the efficacy of these three agents for induction 
and remission was roughly similar. At the moment selection 
of antiTNF agents for induction or salvage therapy is based 
on local availability and regulatory restriction. However, 
while adalinumab and certolizumab have proven effective 
in patients with loss of response to infliximab, no controlled 
data on infliximab as salvage therapy are available.
Effect of certolizumab  
on quality of life
Patients with Crohn’s disease have poor health-related quality 
of life (HRQL). This is usually estimated with the inflam-
matory bowel disease questionnaire (IBDQ) which assesses 
4 aspects of a patient’s life:54
Table 3 Principal characteristics of infliximab, abalimumab and certolizumab
Infliximab Adalimumab Certolizumab
Biological characteristics recombinant chimeric mouse–human 
nonoclonal antiTNF-α antibody
recombinant fully human monoclonal 
antiTNF-α antibody
Fc-free pegylated antiTNF-α
Apoptotic effects Yes Yes No
Administration route intravenous Subcutaneous SubcutaneousClinical and Experimental Gastroenterology 2009:2 67
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1)  symptoms directly related to primary bowel symptoms;
2)  systemic symptoms;
3)  emotional function;
4)  social function.
The IBDQ scores range from 32 to 224, higher scores 
indicating better quality of life. An increase of at least 16 points 
in the total score is regarded as clinically meaningful.55
In Schreiber’s phase II study, for all treatment groups, 
there was an increase in IBDQ total scores within 2 weeks 
of treatment that paralleled the change in CDAI scores. The 
large change from baseline at week 2 was observed in the 
certolizumab 400 mg group (22.8 points compared with 
10.6 points in the placebo group) (p = 0.002). At week 12, 
the IBDQ total scores were 156.5 ± 37.36 in the certoli-
zumab group compared with 140.5 ± 35.88 in the placebo 
group.42
In PRECISE 2, 60% patients in the certolizumab group 
had a IBDQ response at week 26 compared with 43% in the 
placebo group (p  0,001).
These data suggest that certolizumab 400 mg might sig-
nificantly improve the quality of life in patients with moderate 
to severe Crohn’ disease.
Conclusion
AntiTNF agents have an important role in the treatment of 
Crohn’s disease refractory to conventional therapy. Com-
pared with adalinumab and infliximab, certolizumab pegol 
is similarly effective for a rapid induction of response (about 
50% of patients) and long-term maintenance of clinical 
response or remission.
Moreover, certolizumab significantly improves quality 
of life in patients with active Crohn’s disease.
Certolizumab appears to be safe since no clinical trials 
have reported an increased risk of serious adverse events; 
however, more data from longer duration studies and larger 
numbers of patients are still needed.
Of note, certolizumab might be an additional treatment 
option in patients who have lost response to or were intoler-
ant to other antiTNF agents.
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